• 1
    Albright F, Smith PH, Richardson AM 1941 Postmenopausal osteoporosis—its clinical features. JAMA 116:24652473.
  • 2
    Lindsay R, Hart DM, Forrest C, Baird C 1980 Prevention of spinal osteoporosis in oophorectomized women. Lancet 2:11511154.
  • 3
    Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC 1996 Sex steroids, bone mass, and bone loss. A prospective study of pre, peri- and postmenopausal women. J Clin Invest 97:1421.
  • 4
    Ettinger B, Pressman A, Sklarin P, Bauer D, Cauley JA, Cummings SR 1998 Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures. J Clin Endocrinol Metab 83:22392243.
  • 5
    Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR 1998 Hormonal predictors of bone loss in elderly women: A prospective study. J Bone Miner Res 13:11671174.
  • 6
    Cummings SR, Browner WS, Bauer DB, Stone K, Ensrud K, Jamal S, Ettinger B 1998 Endogeneous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 339:733738.
  • 7
    Stepan JJ, Pospichal J, Presl J, Pacovsky V 1987 Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279284.
  • 8
    Seibel M, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R 1993 Urinary hydroxypyridinium crosslinks of collagen and markers of bone resorption and estrogen efficacy in postmenopausal women. J Bone Miner Res 8:881889.
  • 9
    Uebelhart D, Schlemmer A, Johansen J, Gineyts E, Christiansen C, Delmas PD 1991 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72:367373.
  • 10
    Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337349.
  • 11
    Field C, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL 1993 Preventive effects of trandermal 17 beta estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial. Am J Obstet Gynecol 168:114121.
  • 12
    Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate, Dain M-P 1999 A dose-ranging trial of a matrix transdermal 17 beta estradiol for the prevention of bone loss in early postmenopausal women. Bone 24:517523.
  • 13
    Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, Raisz LG 1994 The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366371.
  • 14
    Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture risk in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:15311538.
  • 15
    van Daele PLA, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leewen JPTM, Birkenhager JC, Pols HA 1996 Case-control analysis of bone-resorption markers, disability, and hip fracture: The Rotterdam study. BMJ 312:482483.
  • 16
    Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS 1983 Relationship between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 72:1396.
  • 17
    Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD 1997 Apparent pre and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: The Ofely cohort. J Bone Miner Res 12:683690.
  • 18
    National Osteoporosis Foundation Working Group on Vertebral Fractures 1995 Assessing vertebral fractures: A report by the National Osteoporosis Working Group on vertebral Fractures. J Bone Miner Res 10:518523.
  • 19
    Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR 1999 Defining incident vertebral deformity: A prospective comparison of several approaches. J Bone Miner Res 14:90101.
  • 20
    Garnero P, Grimaux M, Demiaux B, Préaudat C, Seguin P, Delmas PD 1992 Measurement of serum osteocalcin with a human-specific two-site radioimmunoassay. J Bone Miner Res 7:13891397.
  • 21
    Garnero P, Delmas PD 1993 Assessment of the serum levels of bone akaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:10461053.
  • 22
    Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J 1996 Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 46:947954.
  • 23
    Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ 1994 Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:16431649.
  • 24
    Hanson DA, Weiss MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:12511258.
  • 25
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:20222025.
  • 26
    Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C 1998 Serum Crosslaps one step Elisa. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:22812289.
  • 27
    Bremond AG, Claustrat B, Rudigoz RC, Seffert P, Corniau J 1982 Estradiol, androstenedione, and dehydroepiandrosterone sulfate in the ovarian and peripheral blood of postmenopausal patients with and without endometrial cancer. Gynecol Oncol 14:119124.
  • 28
    Duda RJ, O' Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL 1988 Concurrent assays of circulating bone-gla-protein and bone alkaline phosphatase: Effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951957.
  • 29
    Delmas PD, Demiaux B, Malaval L, Chapuy M-C, Meunier PJ 1986 Serum bone-GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 38:6061.
  • 30
    Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD 1994 Markers of bone turnover in hyperthyroidism: Effects of treatment. J Clin Endocrinol Metab 78:955959.
  • 31
    Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD 1999 Markers of bone turnover predict forearm bone loss: A 4-yr follow-up study. J Bone Miner Res 14:16141621.
  • 32
    Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C 1996 Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15 year follow-up study. Bone 19:912.
  • 33
    Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone crosslinks excretion. J Bone Miner Res 10:641649.
  • 34
    Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L 1996 Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline crosslinks. J Bone Miner Res 11:11761184.
  • 35
    Apone S, Lee MY, Eyre DR 1997 Osteoclasts generate crosslinked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 21:129136.
  • 36
    Colwell A, Eastell R 1996 The renal clearance of free and conjugated pyridinium cross-links of collagen. J Bone Miner Res 11:19761980.
  • 37
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD 1998 Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 41:354360.
  • 38
    Fledelius C, Johnsen AH, Closs PC, Bonde M, Qvist P 1997 Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha 1) region. J Biol Chem 272:97559763.
  • 39
    Gineyts E, Cloos PAC, Borel O, Grimaud L, Delmas PD, Garnero P 2000 Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem J 345:481485.
  • 40
    Nordin BEC, Robertson A, Seamark RF, Bridges A, Philcox JC, Need AG, Horowitz M, Morris HA, Deam S 1985 The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 60:651656.
  • 41
    Davidson BJ, Riggs BL, Wahner HW, Judd HL 1983 Endogeneous cortisol and sex steroids in patients with osteoporotic spinal fractures. Obstet Gynecol 61:275.
  • 42
    Tomkinson A, Reeve J, Shaw RW, Noble BS 1997 The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:128135.
  • 43
    Dunstan CR, Evans RA, Hills E, Wong SYP, Higgs RJED 1990 Bone death in hip fracture in the elderly. Calcif Tissue Int 47:270275.